Streetbeat News

Earnings

ITRM

Iterum Therapeutics (NASDAQ:ITRM) is scheduled to release its quarterly earnings report on March 28, 2024, with an estimated EPS of $-0.93. Historical data shows mixed reactions to past earnings, with the last quarter missing estimates but resulting in a 10.76% share price increase. Shares are currently at $1.56, up 57.25% over the last year. Investors are advised to watch for earnings performance and guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 5:01 pm

INLX

Intellinetics (AMEX:INLX) is scheduled to release its quarterly earnings report on March 28, 2024, with an estimated EPS of $0.04. Analysts and investors are keen on not just the earnings beat but also the company's guidance for future growth. Historical data shows a mixed reaction to past earnings reports in terms of stock price movement. As of March 26, INLX shares were trading at $8.28, marking a 106.01% increase over the last 52 weeks, indicating a positive sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 5:01 pm

SHPW

Shapeways Hldgs (NYSE:SHPW) is scheduled to release its quarterly earnings report on March 28, 2024, with an expected EPS of $-0.95. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historical data shows that Shapeways has had a mixed earnings performance in the past, with share price reactions varying post-earnings announcement. Currently, SHPW shares are trading at $1.88, marking a 44.23% decline over the last 52 weeks, indicating a bearish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 5:01 pm

NRXP

NRX Pharmaceuticals (NASDAQ:NRXP) is scheduled to release its quarterly earnings report on March 28, 2024, with analysts expecting an EPS of $-0.07. The company's past performance shows a pattern of beating EPS estimates, leading to positive share price movements the following day. However, shares have declined 27.21% over the last 52 weeks, indicating long-term shareholder dissatisfaction. Investors will be keenly watching for not only the earnings results but also the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 5:01 pm

NVVE

Nuvve Holding (NASDAQ:NVVE) is scheduled to release its quarterly earnings report on March 28, 2024, with an expected EPS of $-5.60. Analysts and investors are keen on whether the company will surpass this estimate and provide positive future guidance. Historical data shows that Nuvve's stock price is significantly influenced by its earnings performance and guidance, with a notable 11.94% drop following a miss last quarter. The stock has experienced a 95.53% decline over the past year, indicating potential concern among long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 5:01 pm

NXGL

NexGel (NASDAQ:NXGL) is scheduled to release its quarterly earnings report on March 28, 2024, with analysts expecting an EPS of $-0.11. Investors are hopeful for a beat on this estimate and positive guidance for future growth. NexGel's stock performance has been strong, with shares up 102.21% over the last 52 weeks, trading at $2.7325 as of March 26.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 5:01 pm

DRIO

DarioHealth (NASDAQ:DRIO) is expected to report a quarterly EPS of $-0.54 on March 28, 2024. Analysts and investors will be looking for the company to beat this estimate and provide positive guidance for the next quarter. DarioHealth's past earnings performance shows a mixed impact on its stock price, with the last quarter's miss leading to a 32.18% increase in share price. Shares are currently trading at $1.515, down 62.14% over the last 52 weeks, indicating a bearish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 5:00 pm

SYK

Stryker Inc. (NYSE:SYK) stock is currently trading at $351.79, marking a 0.63% increase. Over the past month and year, the stock has risen by 1.24% and 26.87%, respectively. Compared to the Health Care Equipment & Supplies industry's P/E ratio of 52.9, Stryker's P/E ratio of 42.47 suggests it might be undervalued or expected to perform worse than its peers.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 5:00 pm

NCNO

nCino, Inc. (NASDAQ:NCNO) reported Q4 earnings surpassing expectations with adjusted earnings of 21 cents per share against estimates of 12 cents. However, quarterly sales of $123.69 million slightly missed the expected $124.62 million. The company provided optimistic FY25 guidance, projecting revenues and adjusted EPS above analyst expectations, leading to a 19.2% surge in its stock price. Following the earnings announcement, analysts from Needham, Baird, and Piper Sandler adjusted their price targets for NCNO.

Portfolio Pulse from Avi Kapoor

March 27, 2024 | 4:58 pm

DRCT

Direct Digital Holdings, Inc. (NASDAQ:DRCT) reported Q4 financial results below analyst expectations, with a loss of 8 cents per share against an expected gain of 26 cents, and quarterly sales of $41.01 million, missing estimates by 37.81%. Despite a 76% revenue growth year-over-year, the company's shares fell 36.3% to $16.82. Analysts from Benchmark, Roth MKM, and Noble Capital Markets adjusted their price targets and ratings following the earnings announcement.

Portfolio Pulse from Avi Kapoor

March 27, 2024 | 4:48 pm